Presenting on the Emerging Growth Conference on February 22 Register Now

Presenting on the Emerging Growth Conference on February 22 Register Now

EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 50 th Emerging Growth Conference on February 22, 2023.

The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

Register for the conference here.

Submit Questions for any of the presenting companies to:
Questions@EmergingGrowth.com

February 22, 2023, Schedule: (Eastern Time)

For updates, follow us on Twitter

8:30
Virtual Lobby opens
Register for the Conference . If you already registered, go back to the registration link and click "Already registered" and enter your email.

9:00
Introduction

9:05 - 9:35
Rail Vision (NASDAQ: RVSN)
Shahar Hania, CEO / Co Founder

9:40 - 10:10
SmartCard Marketing Systems Inc., (OTCQB: SMKG)
Massimo Barone, CEO

10:15 - 10:45
Transition Metals Corp. (OTC Pink: TNTMF) (TSXV: XTM)
Scott Alexander McLean, President / CEO

10:50 - 11:20
Trevi Therapeutics, Inc. (NASDAQ: TRVI)
Jennifer Good, President / CEO,
David Clark, CMO,
Farrell Simon, SVP Commercial and Strategy

11:25 – 11:55
Cloud DX, Inc. (OTCQB: CDXFF) (TSXV: CDX)
Robert Kaul, CEO

12:35 – 1:05
Vivos Therapeutics, Inc. (NASDAQ: VVOS)
Kirk Huntsman, CEO

2:25 – 2:35
Cyngn, Inc. (NASDAQ: CYN)
Ben Landon, VP Business Development

2:40 – 2:50
Regen BioPharma, Inc., (OTC PINK: RGBP) and (OTC PINK: RGBPP)
David Koos, President / CEO & Harry M. Lander, Ph.D. Senior Scientific Consultant

2:55 – 3:05
Renforth Resources Inc., (CSE: RFR) (OTCQB: RFHRF)
Nicole Brewster, President & CEO

3:10 – 3:20
Winning Brands (OTC Pink: WNBD)
Eric Lehner, CEO Winning Brands, Vincent J. Vincent, CEO of GestureTek & Erol Vekil, President of GestureTek

Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

Register for the conference here.

Submit Questions for any of the presenting companies to:
Questions@EmergingGrowth.com

Replays: subscribe to our YouTube Channel

About EmergingGrowth.com
Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

If you believe or know of a company that might fit our audience, contact us here.

Thank you for your interest in our conference, and we look forward to your participation in future conferences.

Contact:

Emerging Growth
Phone: 1-305-330-1985
Email: Conference@EmergingGrowth.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

RFR:CC
The Conversation (0)
Renforth Resources Exhibiting at PDAC Booth #2136

Renforth Resources Exhibiting at PDAC Booth #2136

(TheNewswire)

Renforth Resources Inc.

February 23, 2023 TheNewswire - Renforth Resources Inc. (CSE:RFR) (OTC:RFHRF) (FSE:9RR) (" Renforth" or the "Company") would like to invite interested parties to visit our booth, #2136, during the Prospectors & Developers Convention in Toronto, Ontario to be held at the Metro Convention Centre March 5-8, 2023.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Renforth Resources Presents in Red Cloud's Virtual Webinar Series

Renforth Resources Presents in Red Cloud's Virtual Webinar Series

Renforth Resources (CSE: RFR) is pleased to announce that the company is presenting a live virtual corporate update hosted by Red Cloud Financial Services on February 15th, 2023 at 2:00 pm ET.

We invite our shareholders, and all interested parties to register for the webinar and participate in the live Q&A session at the end of the presentation moderated by Red Cloud.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Renforth Intersects Surface Battery Metals Mineralization in Lalonde Channeling

Renforth Intersects Surface Battery Metals Mineralization in Lalonde Channeling

(TheNewswire)

Renforth Resources Inc.

November 27 th 2022 TheNewswire Pickering, ON - Renforth Resources Inc. (CSE:RFR) (OTC:RFHRF) (FSE:9RR) ("Renforth" or the "Company") is pleased to advise shareholders that channels cut within the 3 stripped trenches at Lalonde, which are being undercut in the current drill program, did intersect surface battery metals mineralization as measured in the field and confirmed by the assay laboratory.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Renforth Raises an Oversubscribed Total of $1,558,100

Renforth Raises an Oversubscribed Total of $1,558,100

(TheNewswire)

Renforth Resources Inc.

November 23, 2022 TheNewswire - Renforth Resources Inc. (CSE:RFR) (OTC:RFHRF) (FSE:9RR) ("Renforth" or the "Company") announces that the previously announced private placement has closed oversubscribed, with a total of $1,558,100 gross funds raised in a combination of flow through and non-flow through funds. The Company has closed the final tranches of the previously announced non-brokered private placement for additional gross proceeds of C$869,300 from the sale of 580,000 non-flow through units of the Company at a price of C$0.035 per unit and 21,225,000 flow-through units of the Company at a price of C$0.04 per flow-through unit. Each non-flow through unit consisted of one common share of the Company and one common share purchase warrant. Each flow through unit consisted of one common share to be issued as a "flow-through share" within the meaning of the Income Tax Act (Canada) and one half of one warrant. Each whole warrant entitles the holder to purchase one common share at a price of C$0.06 for a period of 24 months following the distribution date. In connection to this tranche of the financing, the company paid a cash commission of $44,850 and issued 1,207,000 finders warrants. The finders warrants are exercisable at a price of C$0.06 for a period of 24 months.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Renforth Resources Inc.: Invitation to Red Cloud's 2022 Fall Mining Showcase

Renforth Resources Inc.: Invitation to Red Cloud's 2022 Fall Mining Showcase

Renforth Resources Inc. (CSE: RFR) is pleased to announce that the company will be presenting at Red Cloud's 2022 Fall Mining Showcase. We invite our shareholders and all interested parties to join us there.

The annual conference will be hosted in-person, at the Sheraton Centre Toronto Hotel from November 9-10, 2022.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Trident Royalties PLC Announces Recommended Cash Offer for Trident by Deterra

Trident Royalties PLC Announces Recommended Cash Offer for Trident by Deterra

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
StrategX Elements Corp. Announces $4.5M Charity Flow-Through Private Placement

StrategX Elements Corp. Announces $4.5M Charity Flow-Through Private Placement

StrategX Elements Corp. (CSE: STGX) ("StrategX" or the "Company"), announces that it proposes to undertake an up to $4,500,000 non-brokered private placement of flow-through shares (the "Charity FT Shares") to be sold to charitable purchasers at a price of $0.30 per Charity FT Share. The gross proceeds received from the sale of the Charity FT Shares will be used for work programs on the Company's exploration properties. All securities issued and sold under this financing will be subject to a four-month-and-one-day hold period under securities laws in Canada. The Company expects to complete this Charity FT Share financing on or before June 24, 2024.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Heritage Mining Announces up to $750,000 Non-Brokered Private Placement with lead orders over C$500,000

Heritage Mining Announces up to $750,000 Non-Brokered Private Placement with lead orders over C$500,000

(TheNewswire)

Heritage Mining Ltd.

NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Noble Acquires Mann Twp Claims and Spruce Ridge Units, and Agrees to Purchase Interest in Carnegie Twp Claims

Noble Acquires Mann Twp Claims and Spruce Ridge Units, and Agrees to Purchase Interest in Carnegie Twp Claims

(TheNewswire)

Noble Mineral Exploration Inc.

Toronto, Ontario TheNewswire - June 11, 2024 Noble Mineral Exploration Inc. ( "Noble" or the "Company" ) (TSX-V:NOB, FRANKFURT: NB7, OTCQB:NLPXF) is pleased to provide the following updates:

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
End of the BAPE Public Information Period 

End of the BAPE Public Information Period 

Falco Resources Ltd. (TSX.V: FPC) (" Falco " or the " Corporation ") would like to thank all those who participated and enriched the discussions during the public information period of the Bureau d'audiences publiques sur l'environnement (BAPE) and reiterates its commitment to working closely with the community, environmental groups, and authorities for the success of Falco's Horne 5 Project (" Falco's Horne 5 Project " or the " Project" ).

This information period, which was held from April 24 to June 10, 2024, allowed citizens, groups, the municipality and organizations to learn about the various environmental, economic and social aspects of the Project. During this period, it was also possible to make requests for public consultation or mediation to the Minister of the Environment, the Fight against Climate Change, Wildlife and Parks.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024 at 11:20am ET . Management will also host one-on-one investor meetings. Please find additional details about the event below.

Relmada Therapeutics Corporate Logo (PRNewsFoto/Relmada Therapeutics, Inc.)

2024 Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Presentation Date: Wednesday, June 12, 2024 , 11:20am ET
Webcast: Click Here

Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Goldman Sachs representative to schedule a meeting.

The webcast can also be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors . An archived replay will be available for 90 days following the conclusion of the event.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD).  Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com .

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully carried out, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-302167986.html

SOURCE Relmada Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×